P03.05 Vaccine immunotherapy against human endogenous retrovirus: a focus on anti-herv-k antibodies

Bermejo, AV; Daradoumis, J; Azcoaga, P; Ragonnaud, E; Neukrich, L; Nielsen, KN; Andersoon, AC; Scroedel, S; Thirion, C; Ørskov, C; Caffarel, MM; Holst, PJ

doi:10.1136/jitc-2022-itoc9.33

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent project has been trying to evaluate whether HERV-K would be able to influence the observable attributes in breast cancer through proliferation, cell migration and invasion, and colony formation analyses [169]. This ongoing project intends to employ commercial and natural anti-HERV-K antibodies along with protease inhibitors and putative HERV-K blockers to discover how vaccines composed of anti-HERV-K antibodies could defect immunosuppressive profiles of HERV-K in T cell, NK, and antigen presentation and T cell activation.…”

Section: Anti-herv-k Antibodies As the Future Breast Cancer Treatment?mentioning

confidence: 99%

“…This ongoing project intends to employ commercial and natural anti-HERV-K antibodies along with protease inhibitors and putative HERV-K blockers to discover how vaccines composed of anti-HERV-K antibodies could defect immunosuppressive profiles of HERV-K in T cell, NK, and antigen presentation and T cell activation. The answers to this question could shed light on discovery of novel therapies effective against HERV-K-induced breast cancers [169].…”

Section: Anti-herv-k Antibodies As the Future Breast Cancer Treatment?mentioning

confidence: 99%

See 1 more Smart Citation

Anti-HERV-K Drugs and Vaccines, Possible Therapies against Tumors

Hosseiniporgham

Sechi

2023

Vaccines

View full text Add to dashboard Cite

The footprint of human endogenous retroviruses (HERV), specifically HERV-K, has been found in malignancies, such as melanoma, teratocarcinoma, osteosarcoma, breast cancer, lymphoma, and ovary and prostate cancers. HERV-K is characterized as the most biologically active HERV due to possession of open reading frames (ORF) for all Gag, Pol, and Env genes, which enables it to be more infective and obstructive towards specific cell lines and other exogenous viruses, respectively. Some factors might contribute to carcinogenicity and at least one of them has been recognized in various tumors, including overexpression/methylation of long interspersed nuclear element 1 (LINE-1), HERV-K Gag, and Env genes themselves plus their transcripts and protein products, and HERV-K reverse transcriptase (RT). Therapies effective for HERV-K-associated tumors mostly target invasive autoimmune responses or growth of tumors through suppression of HERV-K Gag or Env protein and RT. To design new therapeutic options, more studies are needed to better understand whether HERV-K and its products (Gag/Env transcripts and HERV-K proteins/RT) are the initiators of tumor formation or just the disorder’s developers. Accordingly, this review aims to present evidence that highlights the association between HERV-K and tumorigenicity and introduces some of the available or potential therapies against HERV-K-induced tumors.

show abstract

Section: Anti-herv-k Antibodies As the Future Breast Cancer Treatment?mentioning

confidence: 99%

Section: Anti-herv-k Antibodies As the Future Breast Cancer Treatment?mentioning

confidence: 99%